You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
|
|---|---|
| Published in |
Clinical Cancer Research, March 2016
|
| DOI | 10.1158/1078-0432.ccr-15-1221 |
| Pubmed ID | |
| Authors |
Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni R. Abdul Razak, Katherine Van Loon, Amita Patnaik, Philippe L. Bedard, Ariceli A. Alfaro, Muralidhar Beeram, Lieve Adriaens, Carrie M. Brownstein, Israel Lowy, Ana Kostic, Pamela A. Trail, Bo Gao, A. Thomas DiCioccio, Lillian L. Siu |
| Abstract |
Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Ang2 with high affinity, but shows no binding to Ang1. The main objectives of this trial were to determine the safety, tolerability, dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of nesvacumab. Nesvacumab was administered intravenously every two weeks (Q2W) with dose escalations from 1 to 20 mg/kg in patients with advanced solid tumors. A total of 47 patients were treated with nesvacumab. No patients in the dose escalation phase experienced DLTs, therefore a maximum tolerated dose (MTD) was not reached. The most common nesvacumab-related adverse events were fatigue (23.4%), peripheral edema (21.3%), decreased appetite and diarrhea (each 10.6%) (all grade ≤ 2). Nesvacumab was characterized by linear kinetics and had a terminal half-life of 6.35 to 9.66 days in a dose-independent manner. Best response by RECIST 1.1 in 43 evaluable patients included 1 partial response (adrenocortical carcinoma) of 24 weeks duration. Two patients with hepatocellular carcinoma had stable disease (SD) > 16 weeks, with tumor regression and >50% decrease in alpha-fetoprotein. Analyses of putative angiogenesis biomarkers in serum and tumor biopsies were uninformative for treatment duration. Nesvacumab safety profile was acceptable at all dose levels tested. Preliminary antitumor activity was observed in patients with treatment-refractory advanced solid tumors. Based on cumulative safety, antitumor activity, PK and PD data, the 20 mg/kg dose was determined to be the RP2D. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Finland | 1 | 2% |
| Unknown | 54 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 16% |
| Student > Ph. D. Student | 6 | 11% |
| Student > Bachelor | 6 | 11% |
| Student > Master | 5 | 9% |
| Other | 5 | 9% |
| Other | 10 | 18% |
| Unknown | 14 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 29% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Agricultural and Biological Sciences | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Nursing and Health Professions | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 16 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2022.
All research outputs
#4,941,334
of 24,293,076 outputs
Outputs from Clinical Cancer Research
#4,387
of 12,976 outputs
Outputs of similar age
#73,139
of 304,278 outputs
Outputs of similar age from Clinical Cancer Research
#48
of 160 outputs
Altmetric has tracked 24,293,076 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,976 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,278 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 160 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.